Combination of Imatinib Mesylate with Autologous Leukocyte-Derived Heat Shock Protein and Chronic Myelogenous Leukemia

2005103 citationsJournal Articlebronze Open Access

Authors

Zihai Li · University of Connecticut

義行高橋 · Society for Immunotherapy of Cancer

Bei Liu · Society for Immunotherapy of Cancer

Elizabeth J. Laska · MaineGeneral Medical Center

Priyamvadha Chakravarthi · University of Connecticut

Judith M. Kulko · University of Connecticut

Robert Bona

Abstract

Autologous Hsp70PC vaccination is feasible and safe. When combined with imatinib mesylate, it is associated with immunologic and possible clinical responses against CML in chronic phase.

Topics & Keywords

Chronic Myeloid Leukemia Treatments Lymphoma Diagnosis and Treatment Eosinophilic Disorders and Syndromes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 11, Issue 12, pp. 4460-4468

DOI: 10.1158/1078-0432.ccr-05-0250

Field-Weighted Citation Impact: 7.09